Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Haohai Biological Technology CoFRA:5HB +1.72%66 5-Year Yield-on-Cost % is 17.40 as of Jul. 28, 2026, which is 258% above its 10-year median of 4.86. GuruFocus rates FRA:5HB with a GF Score™ of 66/100 and a GF Value™ of €2.71 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 150 Biotechnology companies, Shanghai Haohai Biological Technology Co ranks better than 95.33% on this metric.
FRA:5HB's 5-Year Yield-on-Cost % is ranked better than 95.33% of 150
companies
in the Biotechnology industry
Industry Median: 1.695
vs FRA:5HB: 17.40
Shanghai Haohai Biological Technology Co (FRA:5HB) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Shanghai Haohai Biological Technology Co 5-Year Yield-on-Cost % Related Terms
FRA:5HB vs VRTX, REGN, RVMD: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Shanghai Haohai Biological Technology Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Haohai Biological Technology Co 5-Year Yield-on-Cost % vs Biotechnology Industry
Shanghai Haohai Biological Technology Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Shanghai Haohai Biological Technology Co (FRA:5HB) has a 5-Year Yield-on-Cost % of 17.40 as of Jul. 28, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Shanghai Haohai Biological Technology Co and its competitors. This is 258% above median its historical median of 4.86. Over the past decade, Shanghai Haohai Biological Technology Co's 5-Year Yield-on-Cost % has ranged from 2.42 to 17.40. According to the industry distribution chart, Shanghai Haohai Biological Technology Co ranks #7 out of 150 companies in the Biotechnology industry, placing it in the top 4.7%.
Is Shanghai Haohai Biological Technology Co's 5-Year Yield-on-Cost % too high?
Shanghai Haohai Biological Technology Co's current 5-Year Yield-on-Cost % of 17.40 is 258% above median its 10-year median of 4.86. Over the past 10 years, this metric has ranged from a low of 2.42 to a high of 17.40. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.70. Shanghai Haohai Biological Technology Co's value of 17.40 is 926.5% above this industry median. Based on the distribution chart, Shanghai Haohai Biological Technology Co ranks #7 out of 150 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Haohai Biological Technology Co has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haohai Biological Technology Co's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Haohai Biological Technology Co ranks #7 out of 150 companies for 5-Year Yield-on-Cost %. This places Shanghai Haohai Biological Technology Co in the top 5% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 1.70. Shanghai Haohai Biological Technology Co's value of 17.40 is 926.5% above this benchmark. Historically, Shanghai Haohai Biological Technology Co's own 5-Year Yield-on-Cost % has ranged from 2.42 to 17.40 over the past decade. While the company's 10-year median is 4.86 vs. the industry median of 1.70, Shanghai Haohai Biological Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.70, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Haohai Biological Technology Co's current 5-Year Yield-on-Cost % of 17.40 is 926.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Shanghai Haohai Biological Technology Co and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Haohai Biological Technology Co's current 5-Year Yield-on-Cost % is 17.40, which is 258% above median its own 10-year median of 4.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haohai Biological Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co (FRA:5HB) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.71, compared to a current price of €1.77 — trading 34.7% below its estimated fair value. The current 5-Year Yield-on-Cost % is 17.40, which is 258% above median its 10-year median of 4.86 and 926.5% above the Biotechnology industry median of 1.70. Shanghai Haohai Biological Technology Co's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Shanghai Haohai Biological Technology Co (FRA:5HB), the current 5-Year Yield-on-Cost % is 17.40 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Haohai Biological Technology Co (FRA:5HB) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co stock appears to be undervalued.
The current stock price of €1.77 is trading 34.7% below its estimated GF Value™ of €2.71.
GuruFocus considers Shanghai Haohai Biological Technology Co to be Significantly Undervalued.
Key valuation signals for FRA:5HB:
5-Year Yield-on-Cost %: 17.40 (258% above median its 10-year median of 4.86)
GF Value™: €2.71 vs. price of €1.77 (34.7% below fair value)
Industry Position: 926.5% above the Biotechnology median (#7 of 150)
No single metric tells the full story. See the FRA:5HB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Haohai Biological Technology Co Business Description
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.
66GF Score
Get the complete analysis for FRA:5HB
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5HB has been successfully added to your 
